363 related articles for article (PubMed ID: 19523047)
1. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
2. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Ooteman W; Koeter MW; Verheul R; Schippers GM; van den Brink W
Eur Neuropsychopharmacol; 2007 Jul; 17(8):558-66. PubMed ID: 17379484
[TBL] [Abstract][Full Text] [Related]
3. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
4. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
7. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
8. Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
O'Brien CP
Curr Psychiatry Rep; 2008 Oct; 10(5):375-6. PubMed ID: 18803909
[No Abstract] [Full Text] [Related]
9. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
10. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic approaches to the management of alcoholism.
Anton RF
J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
[TBL] [Abstract][Full Text] [Related]
12. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
[TBL] [Abstract][Full Text] [Related]
14. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
15. Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Colagiuri B; Morley K; Boakes R; Haber P
Psychother Psychosom; 2009; 78(3):167-71. PubMed ID: 19270472
[TBL] [Abstract][Full Text] [Related]
16. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
17. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
18. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Kiefer F; Jiménez-Arriero MA; Klein O; Diehl A; Rubio G
Addict Biol; 2008 Mar; 13(1):124-9. PubMed ID: 17573782
[TBL] [Abstract][Full Text] [Related]
19. [Acamprosate and naltrexone: similar efficacy for relapse].
Saitz R
Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
[No Abstract] [Full Text] [Related]
20. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]